Skip to content 
Everyday activities can require greater effort.
He has also discussed injuries related to falls.
Yet his public appearances continued.
So did his work with the Foundation.
The contrast is important.
Fox has never claimed that optimism stopped Parkinson’s from progressing.
It did not.
Nor has he presented his experience as a simple story in which determination defeats disease.
Instead, much of his public message has centered on adapting to what cannot immediately be changed while continuing to work on what can.
And research was one area where change increasingly seemed possible.
Twenty-Five Years of Research Investment
By 2025, The Michael J. Fox Foundation had existed for a quarter century.
During that period, Parkinson’s research changed substantially.
Scientists developed better genetic tools.
Large datasets became available.
Researchers learned more about proteins including alpha-synuclein.
Studies examined genetic factors such as LRRK2 and GBA1.
Biomarker research advanced.
New treatments reached patients.
Clinical research increasingly explored ways to identify disease biology before symptoms become advanced.
The Foundation funded projects throughout that landscape.
By 2026, its cumulative research funding had surpassed $3 billion.
And the organization was not slowing down.
In February and March 2026 alone, it announced more than $195 million for 84 research projects.
Those projects covered a broad range of Parkinson’s research.
Some investigated disease biology.
Others focused on potential treatments.
Others examined ways of improving daily life for people already living with Parkinson’s.
The goal remained ambitious.
But scientific progress rarely arrives as one dramatic breakthrough.
It is usually built piece by piece.
Parkinson’s Remains Without a Cure
Despite decades of research, there is currently no cure for Parkinson’s disease.